| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1535-7163.MCT-07-0397 |
| P698 | PubMed publication ID | 18347152 |
| P50 | author | Jan J. Brosens | Q37618319 |
| Eric W-F Lam | Q55686122 | ||
| Stephen Samuel Myatt | Q57625974 | ||
| Rosaline C-Y Hui | Q114412682 | ||
| P2093 | author name string | Joana R Costa | |
| Stephanie K Guest | |||
| Ana R Gomes | |||
| Richard E Francis | |||
| P433 | issue | 3 | |
| P921 | main subject | doxorubicin | Q18936 |
| leukemia | Q29496 | ||
| multiple drug resistance | Q643839 | ||
| P304 | page(s) | 670-678 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells | |
| P478 | volume | 7 |
| Q90575658 | A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma |
| Q24651455 | A new fork for clinical application: targeting forkhead transcription factors in cancer |
| Q37126122 | A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging |
| Q36838262 | ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance |
| Q41576686 | Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells |
| Q39627333 | Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy |
| Q39219440 | Antileukemic potential of PEGylated gold nanoparticle conjugated with protein toxin (NKCT1) isolated from Indian cobra (Naja kaouthia) venom |
| Q36852597 | Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice. |
| Q64058283 | Chasing the FOXO3: Insights into Its New Mitochondrial Lair in Colorectal Cancer Landscape |
| Q64100312 | Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression |
| Q45641138 | Comparative Aspects of Molecular Mechanisms of Drug Resistance through ABC Transporters and Other Related Molecules in Canine Lymphoma |
| Q28475229 | Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer |
| Q35571896 | DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. |
| Q33934046 | Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp |
| Q35146638 | Deciphering the role of forkhead transcription factors in cancer therapy |
| Q36247462 | Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells |
| Q47805371 | Experimental evidences for miR-30b as a negative regulator of FOXO3 upregulated by kynurenine |
| Q34610210 | FBXO15 regulates P-glycoprotein/ABCB1 expression through the ubiquitin--proteasome pathway in cancer cells. |
| Q42366607 | FOXM1 facilitates gastric cancer cell migration and invasion by inducing Cathepsin D. |
| Q38674456 | FOXO transcription factors in cancer development and therapy |
| Q33959090 | FOXO1A is a target for HER2-overexpressing breast tumors |
| Q43816387 | FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3. |
| Q37376385 | FOXO3a promotes gastric cancer cell migration and invasion through the induction of cathepsin L. |
| Q32884377 | FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. |
| Q92874259 | Forkhead Domains of FOXO Transcription Factors Differ in both Overall Conformation and Dynamics |
| Q38116309 | Forkhead box proteins: tuning forks for transcriptional harmony. |
| Q34161585 | FoxO3a and disease progression |
| Q35237150 | Gene signatures of drug resistance predict patient survival in colorectal cancer |
| Q38796545 | Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription |
| Q28468630 | Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization |
| Q53337645 | Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. |
| Q35227377 | Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis |
| Q48135854 | Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients |
| Q39307072 | Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells. |
| Q36687760 | Mechanisms of doxorubicin resistance in hepatocellular carcinoma |
| Q24603354 | MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer |
| Q50042100 | Microfluidic cell sorting by stiffness to examine heterogenic responses of cancer cells to chemotherapy. |
| Q28384629 | Mitochondria and FOXO3: breath or die |
| Q34460758 | Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicin-resistant uterine cancer |
| Q83225642 | Modulating FOXO3 transcriptional activity by small, DBD-binding molecules |
| Q47993254 | Multidrug resistance in myeloma: seeing the whole picture |
| Q37376285 | Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation |
| Q39638448 | Neither P-gp SNP variants, P-gp expression nor functional P-gp activity predicts MDR in a preliminary study of plasma cell myeloma. |
| Q37718408 | Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma. |
| Q41535058 | Nuclear Localization Marker of FOXO3a: Can it be Used to Predict Doxorubicin Response? |
| Q35133116 | Nuclear proteomics with XRCC3 knockdown to reveal the development of doxorubicin-resistant uterine cancer |
| Q36165185 | OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance |
| Q48126015 | Overexpression of FoxO3a is associated with glioblastoma progression and predicts poor patient prognosis. |
| Q46430249 | Oxidative Stress Promotes Doxorubicin-Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions. |
| Q53401599 | PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo. |
| Q37624466 | Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation |
| Q39435517 | Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin |
| Q47110047 | Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer |
| Q37224293 | RNF168 cooperates with RNF8 to mediate FOXM1 ubiquitination and degradation in breast cancer epirubicin treatment |
| Q91937450 | Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells |
| Q59072649 | Regulations of P-Glycoprotein/ABCB1/MDR1 in Human Cancer Cells |
| Q92152691 | Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells |
| Q94547006 | Restoring Treatment Response in Colorectal Cancer Cells by Targeting MACC1-Dependent ABCB1 Expression in Combination Therapy |
| Q38109317 | Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance. |
| Q61817967 | Role of FoxO Proteins in Cellular Response to Antitumor Agents |
| Q38057689 | Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance |
| Q35082400 | Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma |
| Q36697797 | Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a. |
| Q37701644 | Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells |
| Q91988530 | Synthesis and Characterization of Telmisartan-Derived Cell Death Modulators to Circumvent Imatinib Resistance in Chronic Myeloid Leukemia |
| Q38894243 | Synthesis, antiproliferative activity and molecular properties predictions of galloyl derivatives. |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q38710557 | Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. |
| Q47359487 | The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance |
| Q41842515 | The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia. |
| Q92989510 | The Role of Forkhead Box Proteins in Acute Myeloid Leukemia |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q101564352 | Therapeutic strategies targeting FOXO transcription factors |
| Q38939457 | miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. |
Search more.